Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay

MT Newswires Live

Apr 01

Arovella Therapeutics (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer

cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.

The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.

The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.

The company's shares rose nearly 3% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2624636785"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624636785\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624636785?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624636785","market":"nz","top_or_hot":-1,"title":"Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ALA.AU\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer</p><p>cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.</p><p>The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.</p><p>The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.</p><p>The company's shares rose nearly 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-01 10:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ALA.AU\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer</p><p>cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.</p><p>The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.</p><p>The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.</p><p>The company's shares rose nearly 3% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2624636785","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624636785","pubTimestamp":1775011349,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics  confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor , which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T  cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4022":"陆运","ALA.AU":"AROVELLA THERAPEUTICS LTD","LENZ":"Therapeutics","BK4539":"次新股","BK7096":"制药","BK4230":"旅客陆运","BK7503":"科技股","CAR.AU":"CAR GROUP LTD","BK4139":"生物科技","BK7002":"互动媒体与服务","CAR":"安飞士"},"translate_title":"Arovella Therapeutics在体外试验中证实了靶向Claudin 18.2的CAR抗胰腺癌、胃癌的功能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5,"CAR.AU":1,"LENZ":1.5,"ALA.AU":1},"content_text":"Arovella Therapeutics (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}